EcoDrugPlus

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSAPEG00000016147
Gene Symbol: P2RY6
2 Cross references
183 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSAPEG00000004703
Gene Symbol: RIPK1L
1 Cross references
198 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAPEG00000008272
Gene Symbol: RAMP1
1 Cross references
190 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAPEG00000001433
Gene Symbol: RAMP1
1 Cross references
181 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAPEG00000012854
Gene Symbol: RAMP1
1 Cross references
181 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSAPEG00000013927
Gene Symbol: RPTOR
1 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSAPEG00000012034
Gene Symbol: REN
1 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSAPEG00000024768
Gene Symbol: RET
1 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSAPEG00000019710
Gene Symbol: RARA
1 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSAPEG00000006685
Gene Symbol: RARB
2 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSAPEG00000003710
Gene Symbol: RARG
2 Cross references
383 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSAPEG00000000856
Gene Symbol: ROCK2A
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).